Skip to content 
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California. more
| Time Frame | BIOA | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 1.48% | 2.09% | 3.19% |
| 1-Month Return | -15.16% | -2.49% | 0.37% |
| 3-Month Return | -0.34% | -5.12% | -2.24% |
| 6-Month Return | 232.52% | 5.08% | 4.08% |
| 1-Year Return | 418.66% | 10.71% | 29.66% |
| 3-Year Return | -2.84% | 11.92% | 66.07% |
| Dec '17 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 14.94M | - | - | - | 8.99M | [{"date":"2017-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":60.2,"profit":true}] |
| Cost of Revenue | 22.32M | - | - | - | 213.00K | [{"date":"2017-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":0.95,"profit":true}] |
| Gross Profit | (7.38M) | - | - | - | 8.99M | [{"date":"2017-12-31","value":-82.05,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Margin | (49.39%) | - | - | - | 100.00% | [{"date":"2017-12-31","value":-49.39,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Expenses | 102.63M | 39.97M | 48.40M | 78.19M | 101.78M | [{"date":"2017-12-31","value":100,"profit":true},{"date":"2022-12-31","value":38.94,"profit":true},{"date":"2023-12-31","value":47.16,"profit":true},{"date":"2024-12-31","value":76.19,"profit":true},{"date":"2025-12-31","value":99.16,"profit":true}] |
| Operating Income | (110.01M) | (39.97M) | (48.40M) | (78.19M) | (92.78M) | [{"date":"2017-12-31","value":-11001330400,"profit":false},{"date":"2022-12-31","value":-3996900000,"profit":false},{"date":"2023-12-31","value":-4840000000,"profit":false},{"date":"2024-12-31","value":-7819400000,"profit":false},{"date":"2025-12-31","value":-9278000000,"profit":false}] |
| Total Non-Operating Income/Expense | - | 471.00K | (20.82M) | 14.35M | 24.56M | [{"date":"2017-12-31","value":"-","profit":true},{"date":"2022-12-31","value":1.92,"profit":true},{"date":"2023-12-31","value":-84.75,"profit":false},{"date":"2024-12-31","value":58.41,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Pre-Tax Income | (102.11M) | (39.72M) | (63.85M) | (71.11M) | (80.61M) | [{"date":"2017-12-31","value":-10210504100,"profit":false},{"date":"2022-12-31","value":-3972200000,"profit":false},{"date":"2023-12-31","value":-6385400000,"profit":false},{"date":"2024-12-31","value":-7110900000,"profit":false},{"date":"2025-12-31","value":-8060500000,"profit":false}] |
| Income Taxes | 81.73K | 241.00K | 7.79M | (71.11M) | - | [{"date":"2017-12-31","value":1.05,"profit":true},{"date":"2022-12-31","value":3.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-912.36,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Income After Taxes | - | (39.96M) | (71.65M) | - | - | [{"date":"2017-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | - | (39.72M) | (63.85M) | (71.11M) | (80.61M) | [{"date":"2017-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-3972200000,"profit":false},{"date":"2023-12-31","value":-6385400000,"profit":false},{"date":"2024-12-31","value":-7110900000,"profit":false},{"date":"2025-12-31","value":-8060500000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2017-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | (98.15M) | (39.72M) | (63.85M) | (71.11M) | (80.61M) | [{"date":"2017-12-31","value":-9815147300,"profit":false},{"date":"2022-12-31","value":-3972200000,"profit":false},{"date":"2023-12-31","value":-6385400000,"profit":false},{"date":"2024-12-31","value":-7110900000,"profit":false},{"date":"2025-12-31","value":-8060500000,"profit":false}] |
| EPS (Diluted) | - | - | - | (8.30) | (2.24) | [{"date":"2017-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-830,"profit":false},{"date":"2025-12-31","value":-224,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| BIOA | |
|---|---|
| Cash Ratio | 13.96 |
| Current Ratio | 14.24 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| BIOA | |
|---|---|
| ROA (LTM) | -17.76% |
| ROE (LTM) | -27.09% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| BIOA | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.08 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.92 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| BIOA | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 87.77 |
| P/B | 2.85 |
| Price/FCF | NM |
| EV/R | 55.71 |
| EV/Ebitda | NM |
BioAge Labs, Inc (BIOA) share price today is $16.19
Yes, Indians can buy shares of BioAge Labs, Inc (BIOA) on Vested. To buy
Yes, you can purchase fractional shares of BioAge Labs, Inc (BIOA) via the Vested app. You can start investing in BioAge Labs, Inc (BIOA) with a minimum investment of $1.
You can invest in shares of BioAge Labs, Inc (BIOA) via Vested in three simple steps:
The 52-week high price of BioAge Labs, Inc (BIOA) is $24. The 52-week low price of BioAge Labs, Inc (BIOA) is $3.38.
The price-to-earnings (P/E) ratio of BioAge Labs, Inc (BIOA) is
The price-to-book (P/B) ratio of BioAge Labs, Inc (BIOA) is 2.85
The dividend yield of BioAge Labs, Inc (BIOA) is 0.00%
The market capitalization of BioAge Labs, Inc (BIOA) is $789.52M
The stock symbol (or ticker) of BioAge Labs, Inc is BIOA
Consider the share price of BioAge Labs, Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether BioAge Labs, Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in BioAge Labs, Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the BioAge Labs, Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of BioAge Labs, Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that BioAge Labs, Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
